Clinical Trial: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07255781) titled 'Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy' on Sept. 24.

Brief Summary: The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved by the FDA instead of the standard of care to treat PD), for NAFLD patients who receive Guselkumab for their PD.

Study Start Date: Nov. 30

Study Type: OBSERVATIONAL

Condition: Psoriasis (PsO) PsA (Psoriatic Arthritis) NAFLD (Nonalcoholic Fatty Liver Disease)

Intervention:...